Titre : Transgènes

Transgènes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Multimorbidity
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Transgènes : Questions médicales les plus fréquentes", "headline": "Transgènes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Transgènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-06", "dateModified": "2025-03-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Transgènes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Gènes", "url": "https://questionsmedicales.fr/mesh/D005796", "about": { "@type": "MedicalCondition", "name": "Gènes", "code": { "@type": "MedicalCode", "code": "D005796", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.340.024.340" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Gènes-suicide transgéniques", "alternateName": "Genes, Transgenic, Suicide", "url": "https://questionsmedicales.fr/mesh/D041722", "about": { "@type": "MedicalCondition", "name": "Gènes-suicide transgéniques", "code": { "@type": "MedicalCode", "code": "D041722", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.340.024.340.825.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Transgènes", "alternateName": "Transgenes", "code": { "@type": "MedicalCode", "code": "D019076", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Xia Wang", "url": "https://questionsmedicales.fr/author/Xia%20Wang", "affiliation": { "@type": "Organization", "name": "Chongqing Engineering Research Center for Floriculture, Key Laboratory of Horticulture Science for Southern Mountainous Regions of Ministry of Education, College of Horticulture and Landscape Architecture, Southwest University, Chongqing 400715, China." } }, { "@type": "Person", "name": "Taichi Oguchi", "url": "https://questionsmedicales.fr/author/Taichi%20Oguchi", "affiliation": { "@type": "Organization", "name": "Faculty of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8572, Japan." } }, { "@type": "Person", "name": "Yasir Hasan Siddique", "url": "https://questionsmedicales.fr/author/Yasir%20Hasan%20Siddique", "affiliation": { "@type": "Organization", "name": "Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University , Aligarh , Uttar Pradesh , India." } }, { "@type": "Person", "name": "Falaq Naz", "url": "https://questionsmedicales.fr/author/Falaq%20Naz", "affiliation": { "@type": "Organization", "name": "Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University , Aligarh , Uttar Pradesh , India." } }, { "@type": "Person", "name": "None Rahul", "url": "https://questionsmedicales.fr/author/None%20Rahul", "affiliation": { "@type": "Organization", "name": "Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University , Aligarh , Uttar Pradesh , India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The association between lower urinary tract symptoms secondary to benign prostatic hyperplasia and multimorbidity among Chinese middle-aged and elderly males: evidence based on propensity score matching.", "datePublished": "2024-09-26", "url": "https://questionsmedicales.fr/article/39434733", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.21037/tau-24-268" } }, { "@type": "ScholarlyArticle", "name": "Study protocol for two stepped-wedge interventional trials evaluating the effects of holistic information technology-based patient-oriented management in older multimorbid patients with cancer: The GERONTE trials.", "datePublished": "2024-04-05", "url": "https://questionsmedicales.fr/article/38581958", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jgo.2024.101761" } }, { "@type": "ScholarlyArticle", "name": "Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster randomised controlled trial.", "datePublished": "2024-08-27", "url": "https://questionsmedicales.fr/article/39190222", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10198-024-01718-7" } }, { "@type": "ScholarlyArticle", "name": "Circulating CXCL9, monocyte percentage, albumin, and C-reactive protein as a potential, non-invasive, molecular signature of carotid artery disease in 65+ patients with multimorbidity: a pilot study in Age.It.", "datePublished": "2024-07-23", "url": "https://questionsmedicales.fr/article/39109084", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fendo.2024.1407396" } }, { "@type": "ScholarlyArticle", "name": "Weight changes from early to middle adulthood and cardiometabolic multimorbidity later in life among middle-aged and older adults: a retrospective cohort study from the NHANES 1999-2018.", "datePublished": "2024-02-19", "url": "https://questionsmedicales.fr/article/38440787", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fendo.2024.1306551" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Structures génétiques", "item": "https://questionsmedicales.fr/mesh/D040342" }, { "@type": "ListItem", "position": 4, "name": "Génome", "item": "https://questionsmedicales.fr/mesh/D016678" }, { "@type": "ListItem", "position": 5, "name": "Composants de génome", "item": "https://questionsmedicales.fr/mesh/D040481" }, { "@type": "ListItem", "position": 6, "name": "Gènes", "item": "https://questionsmedicales.fr/mesh/D005796" }, { "@type": "ListItem", "position": 7, "name": "Transgènes", "item": "https://questionsmedicales.fr/mesh/D019076" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Transgènes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Transgènes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Transgènes", "description": "Comment détecte-t-on des transgènes dans un organisme ?\nQuels tests sont utilisés pour analyser les transgènes ?\nLes transgènes peuvent-ils être détectés dans les aliments ?\nQuelles méthodes sont utilisées pour le diagnostic des transgènes ?\nPeut-on identifier des transgènes dans des tissus humains ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Multimorbidity&page=131#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Transgènes", "description": "Quels symptômes peuvent résulter de l'expression de transgènes ?\nLes transgènes provoquent-ils des effets indésirables ?\nY a-t-il des symptômes associés aux aliments transgéniques ?\nLes transgènes peuvent-ils affecter la santé humaine ?\nQuels symptômes sont liés aux thérapies géniques ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Multimorbidity&page=131#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Transgènes", "description": "Comment prévenir les risques liés aux transgènes ?\nPeut-on éviter les aliments transgéniques ?\nQuelles mesures de sécurité sont prises pour les transgènes ?\nComment sensibiliser sur les transgènes ?\nLes organismes de réglementation surveillent-ils les transgènes ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Multimorbidity&page=131#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Transgènes", "description": "Comment les transgènes sont-ils utilisés en médecine ?\nLes transgènes peuvent-ils traiter des maladies ?\nQuels traitements utilisent des transgènes ?\nLes transgènes sont-ils utilisés en oncologie ?\nQuels sont les risques des traitements par transgènes ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Multimorbidity&page=131#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Transgènes", "description": "Quelles complications peuvent survenir avec les transgènes ?\nLes transgènes peuvent-ils causer des maladies ?\nY a-t-il des complications environnementales liées aux transgènes ?\nComment les transgènes affectent-ils la santé publique ?\nLes transgènes peuvent-ils affecter la reproduction ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Multimorbidity&page=131#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Transgènes", "description": "Quels facteurs augmentent les risques liés aux transgènes ?\nLes allergies sont-elles un facteur de risque pour les transgènes ?\nL'environnement joue-t-il un rôle dans les risques des transgènes ?\nLes antécédents médicaux influencent-ils les risques liés aux transgènes ?\nL'âge est-il un facteur de risque pour les effets des transgènes ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Multimorbidity&page=131#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on des transgènes dans un organisme ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des techniques comme la PCR et le séquençage pour identifier les transgènes." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour analyser les transgènes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'analyse de l'ADN par électrophorèse et la hybridation." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils être détectés dans les aliments ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests spécifiques peuvent identifier la présence de transgènes dans les aliments." } }, { "@type": "Question", "name": "Quelles méthodes sont utilisées pour le diagnostic des transgènes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les méthodes incluent la PCR quantitative et les tests de Southern blot." } }, { "@type": "Question", "name": "Peut-on identifier des transgènes dans des tissus humains ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des techniques comme la PCR peuvent détecter des transgènes dans des échantillons de tissus." } }, { "@type": "Question", "name": "Quels symptômes peuvent résulter de l'expression de transgènes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon le transgène, mais peuvent inclure des réactions immunitaires." } }, { "@type": "Question", "name": "Les transgènes provoquent-ils des effets indésirables ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets indésirables peuvent survenir, comme des allergies ou des toxicités." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés aux aliments transgéniques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines personnes peuvent éprouver des symptômes allergiques après consommation." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils affecter la santé humaine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que certains transgènes peuvent avoir des impacts sur la santé." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux thérapies géniques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies géniques peuvent entraîner des réactions comme de la fièvre ou des douleurs." } }, { "@type": "Question", "name": "Comment prévenir les risques liés aux transgènes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La réglementation stricte et les tests de sécurité sont essentiels pour prévenir les risques." } }, { "@type": "Question", "name": "Peut-on éviter les aliments transgéniques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en choisissant des produits bio ou en lisant les étiquettes des aliments." } }, { "@type": "Question", "name": "Quelles mesures de sécurité sont prises pour les transgènes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des études de sécurité et des évaluations environnementales sont réalisées avant leur utilisation." } }, { "@type": "Question", "name": "Comment sensibiliser sur les transgènes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des campagnes d'information et des programmes éducatifs peuvent sensibiliser le public." } }, { "@type": "Question", "name": "Les organismes de réglementation surveillent-ils les transgènes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des organismes comme l'EFSA surveillent l'utilisation et la sécurité des transgènes." } }, { "@type": "Question", "name": "Comment les transgènes sont-ils utilisés en médecine ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont utilisés pour développer des thérapies géniques pour traiter des maladies génétiques." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils traiter des maladies ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les transgènes sont utilisés pour traiter des maladies comme la fibrose kystique." } }, { "@type": "Question", "name": "Quels traitements utilisent des transgènes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements comme la thérapie génique et les vaccins génétiquement modifiés en font partie." } }, { "@type": "Question", "name": "Les transgènes sont-ils utilisés en oncologie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont utilisés pour développer des traitements ciblés contre certains cancers." } }, { "@type": "Question", "name": "Quels sont les risques des traitements par transgènes ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent des réactions immunitaires et des effets secondaires imprévus." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les transgènes ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des réactions allergiques et des effets à long terme non prévus." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils causer des maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Il existe des préoccupations sur le potentiel des transgènes à induire des maladies." } }, { "@type": "Question", "name": "Y a-t-il des complications environnementales liées aux transgènes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des impacts sur la biodiversité et des effets sur les écosystèmes sont possibles." } }, { "@type": "Question", "name": "Comment les transgènes affectent-ils la santé publique ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent poser des risques pour la santé publique, nécessitant une surveillance continue." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils affecter la reproduction ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que certains transgènes pourraient avoir des effets sur la reproduction." } }, { "@type": "Question", "name": "Quels facteurs augmentent les risques liés aux transgènes ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'exposition à des transgènes non réglementés et la consommation d'aliments non testés augmentent les risques." } }, { "@type": "Question", "name": "Les allergies sont-elles un facteur de risque pour les transgènes ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes allergiques peuvent avoir des réactions plus sévères aux aliments transgéniques." } }, { "@type": "Question", "name": "L'environnement joue-t-il un rôle dans les risques des transgènes ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les conditions environnementales peuvent influencer l'impact des transgènes sur la santé." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils les risques liés aux transgènes ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents d'allergies ou de maladies auto-immunes peuvent augmenter les risques." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour les effets des transgènes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants et les personnes âgées peuvent être plus sensibles aux effets des transgènes." } } ] } ] }

Sources (1310 au total)

The association between lower urinary tract symptoms secondary to benign prostatic hyperplasia and multimorbidity among Chinese middle-aged and elderly males: evidence based on propensity score matching.

With the aging population, patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) often face multiple chronic conditions (multimorbidity), significantly impacting their qua... This cross-sectional study utilizes data from the China Health and Retirement Longitudinal Study (CHARLS), involving 6,645 residents aged 45 and above. Data on 14 chronic diseases were collected, with... The prevalence of multimorbidity was significantly higher among middle-aged and elderly individuals with LUTS/BPH compared to those without. Before PSM, LUTS/BPH was positively correlated with the num... In the Chinese population, LUTS/BPH is closely associated with multimorbidity and each of the 14 chronic diseases examined, with a dose-response relationship based on the number of chronic diseases de...

Study protocol for two stepped-wedge interventional trials evaluating the effects of holistic information technology-based patient-oriented management in older multimorbid patients with cancer: The GERONTE trials.

Current hospital-based care pathways are generally single-disease centred. As a result, coexisting morbidities are often suboptimally evaluated and managed, a deficiency becoming increasingly apparent... The GERONTE study is a prospective international, multicentric study consisting of two stepped-wedge trials performed at 16 clinical sites across three European countries. Each trial will include 720 ... GERONTE will evaluate whether this kind of holistic, patient-oriented healthcare management can improve quality of life (primary outcome) and other valuable endpoints in older patients with multimorbi... FRONE: NCT05720910 TWOBE: NCT05423808....

Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster randomised controlled trial.

Evidence on the cost effectiveness of deprescribing in multimorbidity is limited.... To investigate the cost effectiveness of a general practitioner (GP) delivered, individualised medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with... Within trial economic evaluation, from a healthcare perspective and based on a cluster randomised controlled trial with a 6 month follow up and 403 patients (208 Intervention and 195 Control) recruite... On average, the SPPiRE intervention was dominant over usual care, with non-statistically significant mean cost savings of €410 (95% confidence interval (CI): - 2211, 1409) and mean health gains of 0.0... The study observed a pattern towards dominance for the SPPiRE intervention, with high expected cost effectiveness. Notably, observed differences in costs and outcomes were consistent with chance, and ... ISRCTN: 12752680, 20th October 2016....

Circulating CXCL9, monocyte percentage, albumin, and C-reactive protein as a potential, non-invasive, molecular signature of carotid artery disease in 65+ patients with multimorbidity: a pilot study in Age.It.

Carotid endarterectomy (CEA) for the prevention of upcoming vascular and cerebral events is necessary in patients with high-grade stenosis (≥70%). In the framework of the Italian National project Age.... A total of 42 inpatients have been enrolled, including 26 men and 16 women, with a mean age of 74 ± 6 years. Sixteen symptomatic and 26 asymptomatic inpatients with ≥70% carotid stenosis underwent CEA... The two groups of inpatients differ in the expression levels of blood c-miRs-126-5p and -1271-5p (but not in their plaques), which are more expressed in symptomatic subjects. Three cytokines were sign...

Weight changes from early to middle adulthood and cardiometabolic multimorbidity later in life among middle-aged and older adults: a retrospective cohort study from the NHANES 1999-2018.

Weight gain in adulthood can influence the development of diabetes and cardiovascular diseases. It is speculated that weight gain is related to cardiometabolic multimorbility (CMM). This study was des... Data of the National Health and Nutrition Examination Survey (NHANES) 1999-2018 cycles were analyzed in the present study. Weights at age 25 years and 10 years before recruitment were self-reported an... A total of 25,994 participants were included. Across adulthood, compared to stable normal weight, maximal overweight, obesity to non-obesity, non-obesity to obesity, and stable obesity were consistent... Maintaining a stable normal weight can benefit more from the prevention of diabetes, CHD, and CMM. Both weight gain and loss across adulthood were accompanied by increased risks of diabetes, CHD, and ...

Associations of long-term exposure to air pollution and physical activity with the risk of systemic inflammation-induced multimorbidity in Chinese adults: results from the China multi-ethnic cohort study (CMEC).

Previous studies proved the effect of long-term exposure to air pollution or physical activity (PA) on the risk of systemic inflammation-induced multimorbidity (SIIM), while the evidence regarding the... This study included 72,172 participants from China Multi-Ethnic Cohort.The average concentrations of ambient particulate matter pollutants (PM... We found positive associations between long-term air pollution particulates exposure and SIIM, with odds ratios (95%CI) of 1.07 (1.03 to 1.11), 1.18 (1.13 to 1.24), and 1.08 (1.05 to 1.12) per 10 µg/m... Long-term (3 years average) exposure to PM...

Relationship between multimorbidity, functional limitation, and quality of life among middle-aged and older adults: findings from the longitudinal analysis of the 2013-2020 Survey of Health, Ageing, and Retirement in Europe (SHARE).

The increased burden of multimorbidity is restricting individuals' ability to live autonomously, leading to a poorer quality of life. This study estimated trajectories of functional limitation and qua... Data originated from the Survey of Health, Ageing, and Retirement in Europe (SHARE). In Luxembourg, data were obtained between 2013 and 2020, involving 1,585 respondents ≥ 50 years of age. Multimorbid... Middle-aged and older adults living with multimorbidity experienced poorer quality of life throughout the life course and were at a higher risk of functional limitation than those without multimorbidi... Using novel methodological techniques, this study contributes to a better understanding of the longitudinal relationship between functional limitation and quality of life among individuals with and wi...

Association of changes in waist circumference, waist-to-height ratio and weight-adjusted-waist index with multimorbidity among older Chinese adults: results from the Chinese longitudinal healthy longevity survey (CLHLS).

The association of changes in waist circumference (WC), waist-to-height ratio (WHtR) and weight-adjusted-waist index (WWI) with subsequent risk of multimorbidity remains unclear among older Chinese ad... Our study was based on the 2011/2012 wave of the CLHLS whose follow-up surveys were conducted in 2014 and 2017/2018. A total of 2900 participants aged 65 and above at baseline were enrolled. WC, WHtR,... During a mean follow-up time of 4.2 (2.0) years, 906 multimorbidity cases were identified. Compared to participants in the persistently low WC group, those in the WC gain group and the persistently hi... Associations of changes in WC, WHtR and WWI with multimorbidity are significant among older Chinese adults. The findings highlight the importance of evaluating changes in WC, WHtR, and WWI in screenin...

Multimorbidity measured with Charlson Comorbidity Index is not associated with clinically relevant risk of revision after primary total hip arthroplasty: a population-based cohort study on 98,647 patients from the Danish Hip Arthroplasty Register.

Evidence for guiding healthcare professionals on the risks of total hip arthroplasty (THA) in multimorbid patients is sparse. We aimed to examine the association between multimorbidity and the risk of... We identified 98,647 THA patients and subsequent revisions in the Danish Hip Arthroplasty Register from 1995 to 2018. Multimorbidity was measured with the Charlson Comorbidity Index (CCI). Using the C... Overall, the prevalence of patients with low, medium, and high CCI was 70%, 24%, and 6%. The CIF of any revision within 10 years was 6.5% (CI 6.2-6.7) in low and 6.5% (CI 5.8-7.3) in high CCI, with an... Multimorbidity is associated with a minor but not clinically relevant increased risk of revision up to 10 years after primary THA....

Implementation and evaluation of a complex intervention to improve information availability at the interface between inpatient and outpatient care in older patients with multimorbidity and polypharmacy (HYPERION-TransCare) - study protocol for a pilot and feasibility cluster-randomized controlled trial in general practice in Germany.

Despite attempts to improve the cross-sectoral flow of information, difficulties remain in routine healthcare. The resulting negative impact on continuity of care is often associated with poor health ... The idea of the complex intervention has been developed in a previous study. This intervention will be tested in a prospective, multicenter, cluster-randomized (via web tool), controlled pilot trial w... The intervention was developed using a participatory approach involving stakeholders and patients. It aims to empower general practice teams as they provide patient-centered care and play a key role i... The study was registered in DRKS-German Clinical Trials Register: registration number DRKS00027649 (date: 19 January 2022). Date and version identifier 10.07.2023; Version 1.3....